Natera to repay 2017 term loan with proceeds from new convertibles

By Sarah Lizee

Olympia, Wash., April 13 – Natera, Inc. plans to repay its obligations under its 2017 term loan with OrbiMed using proceeds from $250 million of new seven-year convertible notes, according to a press release.

The remainder of the net proceeds will be used for working capital and general corporate purposes and continued investments in research and development of its core technology and development of Natera’s product offerings.

In addition, Natera may use a portion of the net proceeds for acquisitions of complementary businesses, technologies or other assets.

Natera is a San Carlos, Calif.-based genetic testing company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.